PL
ACAD icon

Parkwood LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

Parkwood LLC’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,749
Closed -$825K – 87
2024
Q2 		$825K Buy
50,749
+4,479
+10% +$72.3K 0.1% 97
2024
Q1 		$856K Buy
46,270
+23,806
+106% +$590K 0.08% 149
2023
Q4 		$703K Buy
22,464
+2,116
+10% +$50.5K 0.08% 98
2023
Q3 		$424K Buy
20,348
+1,813
+10% +$49.2K 0.05% 104
2023
Q2 		$444K Buy
18,535
+1,393
+8% +$31K 0.08% 107
2023
Q1 		$323K Sell
17,142
-10,174
-37% -$194K 0.04% 130
2022
Q4 		$435K Buy
27,316
+8,915
+48% +$139K 0.07% 113
2022
Q3 		$301K Sell
18,401
-6,433
-26% -$104K 0.05% 129
2022
Q2 		$350K Buy
24,834
+7,762
+45% +$145K 0.06% 124
2022
Q1 		$413K Sell
17,072
-3,976
-19% -$96.2K 0.07% 104
2021
Q4 		$491K Sell
21,048
-7,505
-26% -$151K 0.08% 94
2021
Q3 		$474K Buy
28,553
+5,136
+22% +$99K 0.06% 102
2021
Q2 		$571K Sell
23,417
-3,039
-11% -$68.6K 0.07% 107
2021
Q1 		$683K Buy
26,456
+988
+4% +$43.5K 0.12% 84
2020
Q4 		$1.36M Buy
+25,468
New +$1.26M 0.17% 84

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Parkwood LLC's ACAD Position: Q3 2024 in Review

Parkwood LLC sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 50,749 shares — an estimated $825K sold.

Parkwood LLC first reported a position in ACAD in Q4 2020 and held it in 15 quarters. The position peaked at $1.36M in Q4 2020. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Parkwood LLC reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Parkwood LLC sold 50,749 Acadia Pharmaceuticals shares in Q3 2024, an estimated $825K.
  • Parkwood LLC first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • Parkwood LLC's Acadia Pharmaceuticals position peaked at $1.36M in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Parkwood LLC's 13F filing for Q3 2024, filed 14 Nov 2024.